These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 12097585)

  • 1. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.
    Grandpre LE; Duke-Cohan JS; Ewald BA; Devoy C; Barouch DH; Letvin NL; Reinherz EL; Baden LR; Dolin R; Seaman MS
    Vaccine; 2009 Mar; 27(10):1549-56. PubMed ID: 19168105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
    de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.
    Belyakov IM; Wyatt LS; Ahlers JD; Earl P; Pendleton CD; Kelsall BL; Strober W; Moss B; Berzofsky JA
    J Virol; 1998 Oct; 72(10):8264-72. PubMed ID: 9733870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
    Naito T; Kaneko Y; Kozbor D
    J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
    Sutter G; Staib C
    Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
    Moss B
    Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
    Volz A; Sutter G
    Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Gilbert SC
    Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.
    Holzer GW; Remp G; Antoine G; Pfleiderer M; Enzersberger OM; Emsenhuber W; Hämmerle T; Gruber F; Urban C; Falkner FG; Dorner F
    J Virol; 1999 Jun; 73(6):4536-42. PubMed ID: 10233911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.
    Staib C; Kisling S; Erfle V; Sutter G
    J Gen Virol; 2005 Jul; 86(Pt 7):1997-2006. PubMed ID: 15958679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.
    Dimier J; Ferrier-Rembert A; Pradeau-Aubreton K; Hebben M; Spehner D; Favier AL; Gratier D; Garin D; Crance JM; Drillien R
    J Virol; 2011 May; 85(10):5016-26. PubMed ID: 21367889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.